Next Article in Journal
Lung Cancer Susceptibility and hOGG1 Ser326Cys Polymorphism: A Meta-Analysis
Next Article in Special Issue
Molecular Pathogenesis of Pancreatic Neuroendocrine Tumors
Previous Article in Journal
Breast Cancer: Surgery at the South Egypt Cancer Institute
Open AccessArticle

CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer

1
Department of General Surgery, Henry Ford Health System, Detroit, MI 48202, USA
2
Department of Diagnostic Radiology, Henry Ford Health System, Detroit, MI 48202, USA
3
Department of Radiation Oncology, Henry Ford Health System, Detroit, MI 48202, USA
*
Author to whom correspondence should be addressed.
Cancers 2010, 2(4), 1779-1793; https://doi.org/10.3390/cancers2041779
Received: 10 September 2010 / Revised: 8 October 2010 / Accepted: 11 October 2010 / Published: 13 October 2010
(This article belongs to the Special Issue Pancreatic Cancer)
Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human malignancy with dismal prognosis and few effective therapeutic options. Novel agents that are safe and effective are urgently needed. Oleanolic acid-derived synthetic triterpenoids are potent antitumorigenic agents, but their efficacy or the mechanism of action for pancreatic cancer has not been adequately investigated. In this study, we evaluated the antitumor activity and the mechanism of action of methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me), a oleanane-derived synthetic triterpenoid for human pancreatic cancer cell lines. CDDO-Me inhibited the growth of both K-ras mutated (MiaPaca2, Panc1 and Capan2) and wild-type K-ras (BxPC3) pancreatic cancer cells at very low concentrations. The growth inhibitory activity of CDDO-Me was attributed to the induction of apoptosis characterized by increased annexin-V-FITC binding and cleavage of PARP-1 and procaspases-3, -8 and-9. In addition, CDDO-Me induced the loss of mitochondrial membrane potential and release of cytochrome C. The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-κB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR). Silencing of Akt or mTOR with gene specific-siRNA sensitized the pancreatic cancer cells to CDDO-Me, demonstrating Akt and mTOR as molecular targets of CDDO-Me for its growth inhibitory and apoptosis-inducing activity. View Full-Text
Keywords: pancreatic cancer; CDDO-Me; apoptosis; Akt/mTOR signaling pathway pancreatic cancer; CDDO-Me; apoptosis; Akt/mTOR signaling pathway
Show Figures

Figure 1

MDPI and ACS Style

Deeb, D.; Gao, X.; Arbab, A.S.; Barton, K.; Dulchavsky, S.A.; Gautam, S.C. CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer. Cancers 2010, 2, 1779-1793.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop